Opening Pharmaview Portal...

Service information

Log på

Know your treatment impact by Real World Studies

The growing need to document the impact of your medical treatment give rise to analyses based on the treatment reality your patients meets: Real World Studies.




Real World Studies discloses the patient treatment reality. Patients expect this kind of information. Health care practitioners (HPC) as well as payers ask for it. Your stakeholders rightfully want to know what works. They want evidence from the real world.

If these demands are critical to your success, we recommend that you:

  • Actively start working with Real World Studies and give patients, HCPs and payers the knowledge they request.
  • Use Real World Studies as yet another tool in your dialogue with stakeholders and as valid input in your own Research & Development.

Real World Studies are observational studies based on data from real life as opposed to randomised clinical studies, which are governed by predefined inclusion criteria and end points. Real World Studies reflect the use of medicine in a real life setting, and are in many cases complementary to both clinical evidence and conventional market analysis and therefore a new source for insights.


​​​Working with DLI MI
At DLI MI we are experienced in working with the vast amount of patient data compiled in clinical databases, prescription registry etc. DLI MI have extensive experience with accessing, analysing and interpreting registry data in observational studies without losing touch with the clinical reality in which patients are treated. We analyse the dynamics behind the market, which leads to actionable insights based on the patient treatment reality. Insights that are valuable, not only to you, but to patients, HCPs and payers.

Get in touch
Reach out if you want to extend your existing knowledge with Real World Studies.

Case: RWE analysis of cost of medicine for ADHD adults
DLI Market Intelligence has conducted a real-world data analysis of adults in stable treatment with attention deficit hyperactivity disorder (ADHD) medicine in order to explore the characteristics and cost of the medicine for adults with ADHD.
Whitepaper: Beyond Real World Evidence
Go beyond Real World Evidence and utilise Real World Data throughout the organisation.

 Kontaktperson webpart ‭[1]‬

Contact me for more information

Arun Micheelsen
Chief Market Researcher
P: +45 39 150 956

 Kontaktperson webpart ‭[2]‬

..Or call me to learn more

Mary Rosenzweig
Chief Advisor
P: +45 39 150 957

25-02-2019 14:09